416 related articles for article (PubMed ID: 27821503)
1. Classification systems for chronic graft-versus-host disease.
Lee SJ
Blood; 2017 Jan; 129(1):30-37. PubMed ID: 27821503
[TBL] [Abstract][Full Text] [Related]
2. Extracorporeal photophoresis: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
[TBL] [Abstract][Full Text] [Related]
3. Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force.
Cuvelier GDE; Schoettler M; Buxbaum NP; Pinal-Fernandez I; Schmalzing M; Distler JHW; Penack O; Santomasso BD; Zeiser R; Angstwurm K; MacDonald KPA; Kimberly WT; Taylor N; Bilic E; Banas B; Buettner-Herold M; Sinha N; Greinix HT; Pidala J; Schultz KR; Williams KM; Inamoto Y; Cutler C; Griffith LM; Lee SJ; Sarantopoulos S; Pavletic SZ; Wolff D
Transplant Cell Ther; 2022 Aug; 28(8):426-445. PubMed ID: 35662591
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD.
Vigorito AC; Campregher PV; Storer BE; Carpenter PA; Moravec CK; Kiem HP; Fero ML; Warren EH; Lee SJ; Appelbaum FR; Martin PJ; Flowers ME;
Blood; 2009 Jul; 114(3):702-8. PubMed ID: 19470693
[TBL] [Abstract][Full Text] [Related]
5. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.
Wolff D; Radojcic V; Lafyatis R; Cinar R; Rosenstein RK; Cowen EW; Cheng GS; Sheshadri A; Bergeron A; Williams KM; Todd JL; Teshima T; Cuvelier GDE; Holler E; McCurdy SR; Jenq RR; Hanash AM; Jacobsohn D; Santomasso BD; Jain S; Ogawa Y; Steven P; Luo ZK; Dietrich-Ntoukas T; Saban D; Bilic E; Penack O; Griffith LM; Cowden M; Martin PJ; Greinix HT; Sarantopoulos S; Socie G; Blazar BR; Pidala J; Kitko CL; Couriel DR; Cutler C; Schultz KR; Pavletic SZ; Lee SJ; Paczesny S
Transplant Cell Ther; 2021 Oct; 27(10):817-835. PubMed ID: 34217703
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report.
Lee SJ; Wolff D; Kitko C; Koreth J; Inamoto Y; Jagasia M; Pidala J; Olivieri A; Martin PJ; Przepiorka D; Pusic I; Dignan F; Mitchell SA; Lawitschka A; Jacobsohn D; Hall AM; Flowers ME; Schultz KR; Vogelsang G; Pavletic S
Biol Blood Marrow Transplant; 2015 Jun; 21(6):984-99. PubMed ID: 25796139
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition.
Fisher SA; Cutler A; Doree C; Brunskill SJ; Stanworth SJ; Navarrete C; Girdlestone J
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009768. PubMed ID: 30697701
[TBL] [Abstract][Full Text] [Related]
9. [Graft-versus-Host Disease (GvHD) - an update : Part 1: Pathophysiology, clinical features and classification of GvHD].
Travnik R; Beckers M; Wolff D; Holler E; Landthaler M; Karrer S
Hautarzt; 2011 Feb; 62(2):139-54; quiz 155. PubMed ID: 21279310
[TBL] [Abstract][Full Text] [Related]
10. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report.
Kitko CL; Pidala J; Schoemans HM; Lawitschka A; Flowers ME; Cowen EW; Tkaczyk E; Farhadfar N; Jain S; Steven P; Luo ZK; Ogawa Y; Stern M; Yanik GA; Cuvelier GDE; Cheng GS; Holtan SG; Schultz KR; Martin PJ; Lee SJ; Pavletic SZ; Wolff D; Paczesny S; Blazar BR; Sarantopoulos S; Socie G; Greinix H; Cutler C
Transplant Cell Ther; 2021 Jul; 27(7):545-557. PubMed ID: 33839317
[TBL] [Abstract][Full Text] [Related]
11. Chronic graft-versus-host disease.
Lee SJ; Vogelsang G; Flowers ME
Biol Blood Marrow Transplant; 2003 Apr; 9(4):215-33. PubMed ID: 12720215
[TBL] [Abstract][Full Text] [Related]
12. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.
Theurich S; Fischmann H; Shimabukuro-Vornhagen A; Chemnitz JM; Holtick U; Scheid C; Skoetz N; von Bergwelt-Baildon M
Cochrane Database Syst Rev; 2012 Sep; (9):CD009159. PubMed ID: 22972135
[TBL] [Abstract][Full Text] [Related]
13. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report.
Pidala J; Kitko C; Lee SJ; Carpenter P; Cuvelier GDE; Holtan S; Flowers ME; Cutler C; Jagasia M; Gooley T; Palmer J; Randolph T; Levine JE; Ayuk F; Dignan F; Schoemans H; Tkaczyk E; Farhadfar N; Lawitschka A; Schultz KR; Martin PJ; Sarantopoulos S; Inamoto Y; Socie G; Wolff D; Blazar B; Greinix H; Paczesny S; Pavletic S; Hill G
Transplant Cell Ther; 2021 Aug; 27(8):632-641. PubMed ID: 33836313
[TBL] [Abstract][Full Text] [Related]
14. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease.
Cooke KR; Luznik L; Sarantopoulos S; Hakim FT; Jagasia M; Fowler DH; van den Brink MRM; Hansen JA; Parkman R; Miklos DB; Martin PJ; Paczesny S; Vogelsang G; Pavletic S; Ritz J; Schultz KR; Blazar BR
Biol Blood Marrow Transplant; 2017 Feb; 23(2):211-234. PubMed ID: 27713092
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and manifestations of chronic graft-versus-host disease.
Filipovich AH
Best Pract Res Clin Haematol; 2008 Jun; 21(2):251-7. PubMed ID: 18503990
[TBL] [Abstract][Full Text] [Related]
16. [2018 update on chronic graft-versus-host disease].
Inamoto Y
Rinsho Ketsueki; 2018; 59(10):2300-2306. PubMed ID: 30305539
[TBL] [Abstract][Full Text] [Related]
17. Validation of NIH consensus criteria for diagnosis and severity-grading of chronic graft-versus-host disease.
Aisa Y; Mori T; Kato J; Yamane A; Kohashi S; Kikuchi T; Okamoto S
Int J Hematol; 2013 Feb; 97(2):263-71. PubMed ID: 23371545
[TBL] [Abstract][Full Text] [Related]
18. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report.
Paczesny S; Hakim FT; Pidala J; Cooke KR; Lathrop J; Griffith LM; Hansen J; Jagasia M; Miklos D; Pavletic S; Parkman R; Russek-Cohen E; Flowers ME; Lee S; Martin P; Vogelsang G; Walton M; Schultz KR
Biol Blood Marrow Transplant; 2015 May; 21(5):780-92. PubMed ID: 25644957
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Late Acute and Chronic Graft-Versus-Host Disease according to the 2014 National Institutes of Health Consensus Criteria in Japanese Patients.
Ito R; Inamoto Y; Inoue Y; Ito A; Tanaka T; Fuji S; Okinaka K; Kurosawa S; Kim SW; Yamashita T; Fukuda T
Biol Blood Marrow Transplant; 2019 Feb; 25(2):293-300. PubMed ID: 30244104
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
